Ultraviolet B eye irradiation aggravates atopic dermatitis via adrenocorticotropic hormone and NLRP3 inflammasome in NC/Nga mice

2017 ◽  
Vol 34 (3) ◽  
pp. 200-210 ◽  
Author(s):  
Keiichi Hiramoto ◽  
Yurika Yamate ◽  
Satoshi Yokoyama
Keyword(s):  
Atopic Dermatitis ◽  
Nlrp3 Inflammasome ◽  
Adrenocorticotropic Hormone ◽  
Ultraviolet B

scholarly journals A novel function of NLRP3 independent of inflammasome as a key transcription factor of IL-33 in epithelial cells of atopic dermatitis

2021 ◽  
Vol 12 (10) ◽  
Author(s):  
Jie Zheng ◽  
Lu Yao ◽  
Yijing Zhou ◽  
Xiaoqun Gu ◽  
Can Wang ◽  
...  
Keyword(s):  
Transcription Factor ◽  
Atopic Dermatitis ◽  
Epithelial Cells ◽  
Mrna Expression ◽  
Nlrp3 Inflammasome ◽  
Myeloid Cells ◽  
Pathological Process ◽  
Inflammasome Activation ◽  
Mice Model ◽  
Nlrp3 Inflammasome Activation

AbstractAtopic dermatitis (AD) is a common chronic pruritic inflammatory skin disorder characterized by recurrent eczematous lesions. Interleukin (IL)−33, a cytokine of the IL-1 family, was found to play an important role in the pathogenesis of AD. As a key component of the inflammasome, NLRP3 has been mostly described in myeloid cells that to mediate inflammasome activation conducted proinflammatory cytokine production of the IL-1 family. However, the role of NLRP3 inflammasome in the pathogenesis of AD, as well as IL-33 processing are highly controversial. Whether NLRP3 can mediate IL-33 expression and secretion independently of the inflammasome in the epithelium of AD has remained unclear. In this article, we found the mRNA expression of Il33 and Nlrp3 were notably increased in the lesional skin of AD patients compared to healthy controls. We then found a significant positive correlation between the expression of Nlrp3 and Il33 in the epithelium of MC903-mediated AD mice model, but no changes were observed for Il36α, Il36γ, Il1β, or Il18 mRNA expression, as well as IL-1β or IL-18 production. Overexpression of NLRP3 in human immortalized epithelial cells increased IL-33 expression, whereas siRNA targeting NLRP3 abolished IL-33 expression. In addition, inhibition of NLRP3 inflammasome activation or caspase-1 activity with MCC950 or VX-765 showed no effect on the expression and secretion of IL-33 in AD mice. Unlike myeloid cells, NLRP3 predominantly located in the nucleus of epithelial cells, which could directly bind to Il33 specific-promoters and transactivate it through an interaction with transcription factor IRF4. Furthermore, NLRP3 deficient mice exhibited a significant alleviated epidermis inflammation and decreased mRNA expression and secretion of IL-33 in MC903-mediated AD mice without interfering with TSLP and IL-1β production. Our results demonstrate a novel ability of NLRP3 to function as a crucial transcription factor of IL-33 in epithelium independently of inflammasome that to mediate the pathological process of AD.

The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy

2006 ◽  
Vol 0 (0) ◽  
pp. 061023114143004-??? ◽  
Author(s):  
T. H. Clayton ◽  
S. M. Clark ◽  
D. Turner ◽  
V. Goulden
Keyword(s):  
Atopic Dermatitis ◽  
Ultraviolet B ◽  
Severe Atopic Dermatitis

Impaired NLRP3 inflammasome expression and function in atopic dermatitis due to Th2 milieu

Allergy ◽  
2014 ◽  
Vol 69 (8) ◽  
pp. 1058-1067 ◽  
Author(s):  
M. Niebuhr ◽  
K. Baumert ◽  
A. Heratizadeh ◽  
I. Satzger ◽  
T. Werfel
Keyword(s):  
Atopic Dermatitis ◽  
Nlrp3 Inflammasome ◽  
And Function

A Short Cycle of Narrow-Band UVB Phototherapy in the Early Phase of Dupilumab Therapy Can Provide a Quicker Improvement of Severe Atopic Dermatitis

Dermatology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Mariateresa Rossi ◽  
Chiara Rovati ◽  
Mariachiara Arisi ◽  
Cesare Tomasi ◽  
Irene Calzavara-Pinton ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Narrow Band ◽  
Ultraviolet B ◽  
Adult Patients ◽  
Severe Atopic Dermatitis ◽  
Treatment Regimens ◽  
Short Course ◽  
Receive Treatment ◽  
Uvb Phototherapy

<b><i>Background:</i></b> Since the best clinical response to dupilumab is achieved after 12–16 weeks, a combination therapy at the beginning of the treatment could be a helpful strategy to reach a faster response in patients with severe atopic dermatitis (AD). <b><i>Objectives:</i></b> To quantify the benefit of a combination of dupilumab treatment with a short course of narrow-band ultraviolet B (NB-UVB) phototherapy. <b><i>Methods:</i></b> In the present pilot study adult patients suffering from severe AD were enrolled with a 2:1 ratio to receive treatment with dupilumab alone or dupilumab plus NB-UVB phototherapy, for 12 weeks. After the twelfth week, all patients received dupilumab only. A follow-up visit took place after 16 weeks. Both clinician-oriented and patient-oriented scores were assessed at baseline (T0) and after 4 (T1), 12 (T2) and 16 (T3) weeks. <b><i>Results:</i></b> Forty-five adult patients were enrolled in the study. Both treatment regimens were well tolerated and very effective on all measured scores (EASI, SCORAD, BSA, NRS of itching, NRS of sleep loss, DLQI, POEM and HADS), but the combined regimen led to a more robust clinical improvement of lesions and relief of symptoms after 4 weeks. However, after 12 and 16 weeks, the additional therapeutic effect of phototherapy weakened. <b><i>Conclusion:</i></b> NB-UVB phototherapy can provide a faster remission of severe AD in the first few weeks of dupilumab therapy.

scholarly journals Narrowband ultraviolet B phototherapy improves quality of life of psoriasis and atopic dermatitis patients up to 3 months: Results from an observational multicenter study

2019 ◽  
Vol 35 (5) ◽  
pp. 332-338 ◽  
Author(s):  
Liisa Väkevä ◽  
Sirkka Niemelä ◽  
Meri Lauha ◽  
Rafael Pasternack ◽  
Anna Hannuksela‐Svahn ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Multicenter Study ◽  
Ultraviolet B

scholarly journals Shifts in the Skin Microbiota after UVB Treatment in Adult Atopic Dermatitis

Dermatology ◽  
2021 ◽  
pp. 1-12
Author(s):  
Astrid Haaskjold Lossius ◽  
Olav Sundnes ◽  
Anna Cäcilia Ingham ◽  
Sofie Marie Edslev ◽  
Jørgen Vildershøj Bjørnholt ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Temporal Dynamics ◽  
Skin Barrier ◽  
16S Rrna Gene Sequencing ◽  
Ultraviolet B ◽  
Rrna Gene ◽  
Skin Microbiota ◽  
Lesional Skin ◽  
Before And After ◽  
Nose And Throat

<b><i>Background:</i></b> The pathophysiology in atopic dermatitis (AD) is not fully understood, but immune dysfunction, skin barrier defects, and alterations of the skin microbiota are thought to play important roles. AD skin is frequently colonized with <i>Staphylococcus aureus</i> (<i>S. aureus</i>) and microbial diversity on lesional skin (LS) is reduced compared to on healthy skin. Treatment with narrow-band ultraviolet B (nb-UVB) leads to clinical improvement of the eczema and reduced abundance of <i>S. aureus</i>. However, in-depth knowledge of the temporal dynamics of the skin microbiota in AD in response to nb-UVB treatment is lacking and could provide important clues to decipher whether the microbial changes are primary drivers of the disease, or secondary to the inflammatory process. <b><i>Objectives:</i></b> To map the temporal shifts in the microbiota of the skin, nose, and throat in adult AD patients after nb-UVB treatment. <b><i>Methods:</i></b> Skin swabs were taken from lesional AD skin (<i>n</i> = 16) before and after 3 treatments of nb-UVB, and after 6–8 weeks of full-body treatment. We also obtained samples from non-lesional skin (NLS) and from the nose and throat. All samples were characterized by 16S rRNA gene sequencing. <b><i>Results:</i></b> We observed shifts towards higher diversity in the microbiota of lesional AD skin after 6–8 weeks of treatment, while the microbiota of NLS and of the nose/throat remained unchanged. After only 3 treatments with nb-UVB, there were no significant changes in the microbiota. <b><i>Conclusion:</i></b> Nb-UVB induces changes in the skin microbiota towards higher diversity, but the microbiota of the nose and throat are not altered.

Sign in / Sign up

Export Citation Format

Share Document